- Home
- IONS vs ARWR Comparison
IONS vs ARWR Comparison
Compare IONS & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ARWR
- Stock Information
- Founded
- IONS 1989
- ARWR 2003
- Country
- IONS United States
- ARWR United States
- Employees
- IONS N/A
- ARWR N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- IONS Health Care
- ARWR Health Care
- Exchange
- IONS Nasdaq
- ARWR Nasdaq
- Market Cap
- IONS 6.8B
- ARWR 5.9B
- IPO Year
- IONS 1991
- ARWR 1993
- Fundamental
- Price
- IONS $72.93
- ARWR $40.16
- Analyst Decision
- IONS Strong Buy
- ARWR Buy
- Analyst Count
- IONS 21
- ARWR 9
- Target Price
- IONS $80.71
- ARWR $47.44
- AVG Volume (30 Days)
- IONS 2.9M
- ARWR 1.6M
- Earning Date
- IONS 10-29-2025
- ARWR 11-25-2025
- Dividend Yield
- IONS N/A
- ARWR N/A
- EPS Growth
- IONS N/A
- ARWR N/A
- EPS
- IONS N/A
- ARWR N/A
- Revenue
- IONS $966,957,000.00
- ARWR $572,976,000.00
- Revenue This Year
- IONS $27.96
- ARWR $21,287.22
- Revenue Next Year
- IONS $2.33
- ARWR N/A
- P/E Ratio
- IONS N/A
- ARWR N/A
- Revenue Growth
- IONS 20.41
- ARWR 2816.20
- 52 Week Low
- IONS $23.95
- ARWR $9.57
- 52 Week High
- IONS $76.78
- ARWR $43.69
- Technical
- Relative Strength Index (RSI)
- IONS 55.70
- ARWR 56.03
- Support Level
- IONS $68.22
- ARWR $39.33
- Resistance Level
- IONS $74.50
- ARWR $41.79
- Average True Range (ATR)
- IONS 3.36
- ARWR 2.31
- MACD
- IONS -0.55
- ARWR -0.23
- Stochastic Oscillator
- IONS 64.72
- ARWR 46.29
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.